More Results from the TRAVERSE Trial of Testosterone Therapy

These findings argue against providing testosterone supplementation for men with age-related declining testosterone levels.

In the randomized TRAVERSE trial, about 5200 middle-aged or older men (mean age, 63) with previous cardiovascular (CV) disease or multiple CV risk factors, blood testosterone levels between 100 and 300 ng/dL, and symptoms that could reflect hypogonadism received testosterone therapy or placebo. The primary results, published in mid-2023, showed no excess risk for adverse CV events after ≈2 years (NEJM JW Gen Med Jul 15 2023 and N Engl J Med 2023; 389:107). The researchers took advantage of this huge study population to explore other aspects of testosterone supplementation and published results of several substudies during 2024.

Among ≈1200 participants with low libido, testosterone therapy led to a small mean increase in behaviors associated…

Authors

Thomas L. Schwenk, MD

Disclosures

Editorial BoardsUpToDate

Thomas L. Schwenk, MD

Disclosures

Editorial BoardsUpToDate

Allan S. Brett, MD

Disclosures

Nothing to disclose

Allan S. Brett, MD

Disclosures

Nothing to disclose

More Results from the TRAVERSE Trial of Testosterone Therapy

Topics

Authors